Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies

  title={Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies},
  author={Fengying Huang and Chen Zhou and Xiao-yan Zhang and Ye Shen and Hong-wen Zhang and Yong-Qing Wang and Luning Sun},
  pages={1199 - 1206}
Abstract Voriconazole (VRC) is a first-line drug for the treatment of invasive fungal infections (IFIs) and an inhibitor of CYP3A activity. The aims of this study are to investigate the influence of related factors on the plasma concentration of voriconazole and the effect of voriconazole on the activity of CYP3A in patients with haematological malignancies. A total of 89 patients received an initial dose of 6 mg/kg followed by 4 mg/kg every 12 h were included in the study. Blood samples were… 



Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.

The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.

High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness

A rapid molecular method based on high-resolution melting to characterize polymorphisms of the gene that encodes this enzyme are known to contribute to variability in voriconazole exposure and could offer a useful tool to individually optimize therapy and reduce expenses in patients with fungal infections.

Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China

Therapeutic drug monitoring (TDM) of voriconazole could help to individualize antifungal therapy for children and provide guidelines for TDM and dosing optimization in Asian children.

Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.

The data indicate that voriconazole is a substrate for CYP2C9, CYP 2C19, and CYP3A4, with CYP1C9 involvement being minimal in human liver microsomes, and Genotype status for CYp2C19 and/or coadministration of drugs that modulate CYP7A4 activities could effect voriconsazole plasma levels.

Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy

This manuscript reviews the pharmacogenomics (i.e. the influence of genetics on drug disposition) of triazole antifungal agents related to their CYP-mediated metabolism and summarizes their implications on triazoles efficacy, safety, and tolerability.

CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

Multiple regression analysis of voriconazole apparent oral clearance revealed that 49% of its variance can be explained solely by the CYP2C19 polymorphism (P < .0001).

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Assignment of CYP2C19*17 homozygotes as extensive metabolizers rather than ultrarapid metabolizers is adequate and genotyping is unlikely to have clinical utility except for drugs with very narrow therapeutic indices.

Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society

An evidence-based practice guideline for VRZ-individualized medication is developed, which provided comprehensive and practical recommendations for health care providers and exposed several research gaps to improve VRZ use.